CollPlant Biotechnologies (ADR)
Produces plant-derived recombinant human collagen for bioinks, regenerative products, and aesthetics development.
COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS
LightSolver is pioneering pure photonic computing, bringing a new computing architecture to the public markets to address the speed, energy and heat limitations of semiconductor-based computing LightSolver has developed the world's first Laser Processing Unit™ (LPU™), combining the advantages of classical and quantum computing in a compact platform that operates without cryogenic or other extreme conditions and is designed for commercial deployment. Commercial validation is underway with global leaders across mission-critical industries, including Boeing, a top-tier global financial institution, leading defense companies, oil and gas and energy companies, and leading engineering software organizations.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT
REHOVOT, Israel, June 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 7,647,061 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof), unregistered series A warrants to purchase up to 7,647,061 ordinary shares and unregistered series B warrants to purchase up to 15,294,122 ordinary shares, in a private placement at a combined purchase price of $0.34 per ordinary share and accompanying warrants (or $0.3399 per ordinary share equivalent and accompanying warrants). The series A warrants will have an exercise price of $0.34 per share, will be exercisable on the date of shareholder approval (the "Shareholder Approval Date") and will expire two years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants.
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
REHOVOT, Israel, May 29, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics applications, today announced financial results for the first quarter of 2026 and provided a corporate update. "In the first quarter of 2026, we initiated discussions with several leading strategic players to explore potential collaborations, primarily in the medical aesthetics field," said Yehiel Tal, Chairperson and Chief Executive Officer of CollPlant Biotechnologies.
CollPlant Issues Letter to Shareholders
REHOVOT, Israel, April 13, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-derived recombinant human collagen (rhCollagen), is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal. Dear Shareholders, This morning, we announced the termination of our development agreement with AbbVie.
Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Inhibrx Biosciences (NASDAQ:INBX)
Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and CollPlant Biotechnologies (NASDAQ: CLGN - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation. Risk and Volatility Inhibrx Biosciences has a
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
REHOVOT, Israel, March 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived rhCollagen for tissue regeneration and medical aesthetics, today announced its 2025 financial results and provided a corporate update. "Over the past year, we have made meaningful progress across all fronts-from advancing our collaborative programs to building momentum in our proprietary pipeline and commercial product portfolio.
CollPlant Biotechnologies Launches Redesigned Corporate Website
REHOVOT, Israel, March 18, 2026 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-derived recombinant human collagen (rhCollagen), today announced the launch of its redesigned corporate website at www.collplant.com . The new website provides expanded information regarding the Company's technology platform, product pipeline, strategic collaborations and corporate governance, and is intended to enhance transparency and accessibility for investors, partners, and other stakeholders.
CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler
Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product Candidate REHOVOT, Israel, Feb. 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal filler technology currently under development for the aesthetic market. The allowed patent application covers a polymerizable solution and its use in tissue augmentation.
CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex
BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility REHOVOT, Israel, Feb. 23, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications. BioFlex is engineered to support the biofabrication of advanced tissue models for drug discovery, as well as the development of engineered tissues and transplantable organs.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING
REHOVOT, Israel, Feb. 5, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,600,000 of the Company's ordinary shares at a purchase price of $1.25 per share in a registered direct offering. In addition, in a concurrent private placement, the Company will issue unregistered series A warrants to purchase up to 1,600,000 ordinary shares and unregistered series B warrants to purchase up to 1,600,000 ordinary shares.
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new partnership with a U.S.-based logistics center scheduled to become operational this quarter and under new commercial leadership for this region Recent developments suggest CollPlant's rhCollagen will have a significant contribution towards innovation in the areas of non-animal alternatives for medical and research Plan for cost reductions and program prioritization in place to extend cash runway REHOVOT, Israel , Nov. 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the third quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer, remarked, "CollPlant continued to advance innovation this quarter beyond its core development programs.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS
REHOVOT, Israel , Nov. 18, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 26, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics.
CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada
-- New North American logistics center will provide expanded distribution for CollPlant's rhCollagen and BioInks as well as enable logistical efficiencies -- REHOVOT, Israel , Oct. 27, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the expansion of its distribution footprint into North America through a new partnership with a U.S.-based logistics center. Scheduled to become operational this quarter, the logistics hub will provide full cGMP-compliant storage and distribution services and will serve as a clinical supply depot.
CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology
A head-to-head study by Israel's Technion found that CollPlant's rhCollagen-based bioink, Collink.3D ™, outperformed Matrigel®, a leading extracellular matrix, in supporting structured tissue formation. The findings suggest Collink.3D ™ could offer a consistent, tunable, and animal-free alternative for advanced tissue engineering and research applications.
First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk
The bioprinted skin model is designed to serve as an alternative to animal testing for preclinical research. According to a scientific article published in the Archives of Dermatological Research, the model developed by Mayo Clinic researchers combines CollPlant's plant-derived recombinant human collagen (rhCollagen) with distinct and essential human skin cell types.
CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler
CollPlant is now moving towards clinical trials and scaling and optimizing its manufacturing to ensure readiness for the upcoming clinical trials REHOVOT, Israel , Sept. 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary non-animal recombinant human collagen (rhCollagen), today announced positive results from its non-clinical program evaluating its photocurable dermal filler, as well as plans to advance this product candidate into clinical trials.
CollPlant to Present at the 2025 International Conference on Biofabrication
REHOVOT, Israel , Sept. 2, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced its participation in the annual meeting of The International Society of Biofabrication: the International Conference on Biofabrication 2025, to be held September 14–17, 2025, at the Palace of Culture and Science in Warsaw, Poland.
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- Sales of rhCollagen and bioinks primed for augmentation following new U.S.-based commercial executive hire - - Raised $3.6 million in registered direct offering in second quarter - REHOVOT, Israel , Aug. 20, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer commented, "In recent months, CollPlant has been making strong progress with its photocurable dermal and soft tissue filler program, completing additional testing and preparing for the clinical phase.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS
REHOVOT, Israel , Aug. 5, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the second quarter on Wednesday, August 20, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics.